A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia

Herbert Y. Meltzer, William V Bobo, Myung A. Lee, Philip Cola, Karuna Jayathilake

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Clozapine has been shown to be superior to typical neuroleptic drugs for treating positive symptoms in treatment-resistant (TR) schizophrenia. Long-term data from randomized clinical trials comparing clozapine with typical neuroleptics in non-TR schizophrenia are rare. We previously reported that clozapine was superior to typical neuroleptic drugs in some domains of cognition in recent onset non-TR schizophrenia. We now present data on psychopathology and quality of life from this randomized, flexibly dosed, 24-month study of clozapine vs. typical neuroleptics in non-TR schizophrenia patients. Both treatments produced significant improvement in measures of psychopathology, quality of life, and global function, with minor exceptions. There was no difference in extrapyramidal side effects between the patients treated with clozapine or typical neuroleptics. However, significantly more relapse/rehospitalization drop-outs occurred in the typical neuroleptic group. Two patients treated with typical neuroleptics, but none treated with clozapine, became non-responsive to treatment. Clozapine was associated with significantly greater weight gain. Clozapine and typical neuroleptic drugs appear to produce equivalent improvement in psychopathology in patients with non-TR schizophrenia. Clozapine may be more effective than typical neuroleptics for treatment retention and prevention of relapse, but it produces more severe metabolic side effects. These considerations should be taken into account in decisions of how best to utilize clozapine in the treatment of schizophrenia.

Original languageEnglish (US)
Pages (from-to)286-293
Number of pages8
JournalPsychiatry Research
Volume177
Issue number3
DOIs
StatePublished - May 2010
Externally publishedYes

Fingerprint

Clozapine
Antipsychotic Agents
Schizophrenia
Psychopathology
Quality of Life
Therapeutics
Secondary Prevention
Cognition
Weight Gain
Randomized Controlled Trials
Recurrence

Keywords

  • Clozapine
  • Efficacy
  • Relapse
  • Schizophrenia
  • Treatment-resistant
  • Typical neuroleptics
  • Weight gain

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia. / Meltzer, Herbert Y.; Bobo, William V; Lee, Myung A.; Cola, Philip; Jayathilake, Karuna.

In: Psychiatry Research, Vol. 177, No. 3, 05.2010, p. 286-293.

Research output: Contribution to journalArticle

Meltzer, Herbert Y. ; Bobo, William V ; Lee, Myung A. ; Cola, Philip ; Jayathilake, Karuna. / A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia. In: Psychiatry Research. 2010 ; Vol. 177, No. 3. pp. 286-293.
@article{807afd659ca74d8cbf07dbb6b7867abe,
title = "A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia",
abstract = "Clozapine has been shown to be superior to typical neuroleptic drugs for treating positive symptoms in treatment-resistant (TR) schizophrenia. Long-term data from randomized clinical trials comparing clozapine with typical neuroleptics in non-TR schizophrenia are rare. We previously reported that clozapine was superior to typical neuroleptic drugs in some domains of cognition in recent onset non-TR schizophrenia. We now present data on psychopathology and quality of life from this randomized, flexibly dosed, 24-month study of clozapine vs. typical neuroleptics in non-TR schizophrenia patients. Both treatments produced significant improvement in measures of psychopathology, quality of life, and global function, with minor exceptions. There was no difference in extrapyramidal side effects between the patients treated with clozapine or typical neuroleptics. However, significantly more relapse/rehospitalization drop-outs occurred in the typical neuroleptic group. Two patients treated with typical neuroleptics, but none treated with clozapine, became non-responsive to treatment. Clozapine was associated with significantly greater weight gain. Clozapine and typical neuroleptic drugs appear to produce equivalent improvement in psychopathology in patients with non-TR schizophrenia. Clozapine may be more effective than typical neuroleptics for treatment retention and prevention of relapse, but it produces more severe metabolic side effects. These considerations should be taken into account in decisions of how best to utilize clozapine in the treatment of schizophrenia.",
keywords = "Clozapine, Efficacy, Relapse, Schizophrenia, Treatment-resistant, Typical neuroleptics, Weight gain",
author = "Meltzer, {Herbert Y.} and Bobo, {William V} and Lee, {Myung A.} and Philip Cola and Karuna Jayathilake",
year = "2010",
month = "5",
doi = "10.1016/j.psychres.2010.02.018",
language = "English (US)",
volume = "177",
pages = "286--293",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia

AU - Meltzer, Herbert Y.

AU - Bobo, William V

AU - Lee, Myung A.

AU - Cola, Philip

AU - Jayathilake, Karuna

PY - 2010/5

Y1 - 2010/5

N2 - Clozapine has been shown to be superior to typical neuroleptic drugs for treating positive symptoms in treatment-resistant (TR) schizophrenia. Long-term data from randomized clinical trials comparing clozapine with typical neuroleptics in non-TR schizophrenia are rare. We previously reported that clozapine was superior to typical neuroleptic drugs in some domains of cognition in recent onset non-TR schizophrenia. We now present data on psychopathology and quality of life from this randomized, flexibly dosed, 24-month study of clozapine vs. typical neuroleptics in non-TR schizophrenia patients. Both treatments produced significant improvement in measures of psychopathology, quality of life, and global function, with minor exceptions. There was no difference in extrapyramidal side effects between the patients treated with clozapine or typical neuroleptics. However, significantly more relapse/rehospitalization drop-outs occurred in the typical neuroleptic group. Two patients treated with typical neuroleptics, but none treated with clozapine, became non-responsive to treatment. Clozapine was associated with significantly greater weight gain. Clozapine and typical neuroleptic drugs appear to produce equivalent improvement in psychopathology in patients with non-TR schizophrenia. Clozapine may be more effective than typical neuroleptics for treatment retention and prevention of relapse, but it produces more severe metabolic side effects. These considerations should be taken into account in decisions of how best to utilize clozapine in the treatment of schizophrenia.

AB - Clozapine has been shown to be superior to typical neuroleptic drugs for treating positive symptoms in treatment-resistant (TR) schizophrenia. Long-term data from randomized clinical trials comparing clozapine with typical neuroleptics in non-TR schizophrenia are rare. We previously reported that clozapine was superior to typical neuroleptic drugs in some domains of cognition in recent onset non-TR schizophrenia. We now present data on psychopathology and quality of life from this randomized, flexibly dosed, 24-month study of clozapine vs. typical neuroleptics in non-TR schizophrenia patients. Both treatments produced significant improvement in measures of psychopathology, quality of life, and global function, with minor exceptions. There was no difference in extrapyramidal side effects between the patients treated with clozapine or typical neuroleptics. However, significantly more relapse/rehospitalization drop-outs occurred in the typical neuroleptic group. Two patients treated with typical neuroleptics, but none treated with clozapine, became non-responsive to treatment. Clozapine was associated with significantly greater weight gain. Clozapine and typical neuroleptic drugs appear to produce equivalent improvement in psychopathology in patients with non-TR schizophrenia. Clozapine may be more effective than typical neuroleptics for treatment retention and prevention of relapse, but it produces more severe metabolic side effects. These considerations should be taken into account in decisions of how best to utilize clozapine in the treatment of schizophrenia.

KW - Clozapine

KW - Efficacy

KW - Relapse

KW - Schizophrenia

KW - Treatment-resistant

KW - Typical neuroleptics

KW - Weight gain

UR - http://www.scopus.com/inward/record.url?scp=77952673653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952673653&partnerID=8YFLogxK

U2 - 10.1016/j.psychres.2010.02.018

DO - 10.1016/j.psychres.2010.02.018

M3 - Article

C2 - 20378185

AN - SCOPUS:77952673653

VL - 177

SP - 286

EP - 293

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 3

ER -